SEA - Stress EEG Assessment System
Technology Introduction:
Technological InnovationAI analyzes 90 seconds of resting-state brainwaves and converts them into a clear SEA Index for objective depression risk assessment in 10–15 minutes.
Competitive Advantages
An integrated platform combining an in-house medical-grade EEG device, signal processing, AI analytics, and automated reporting for seamless deployment.
Important Achievements
TFDA-cleared AI SaMD in 2023; validated in 400+ participants at three medical centers.
Industrial Applications:
SEA combines a medical-grade EEG device with cloud-based AI to turn a 90-second resting-state recording into a clear risk indicator. It complements questionnaires and interviews with objective data, supporting more informed communication and follow-up. Suitable for psychiatry, neurology, health screening, and community programs, SEA helps identify individuals who may benefit from earlier mental health support.
HippoScreen Neurotech Corp.
HippoScreen Neurotech Corp. (HNC) was established in March 2019 by Compal Computer's direct investment in the research team of Professor Liu, Yi-Hung. The company takes EEG signal processing and artificial intelligence technology as the core, aiming to develop EEG-assisted diagnosis and medical services. Its self-developed EEG amplifier cleared FDA 510(k) at the end of 2020, completed the TFDA review, and received approval for the medical device in March 2021, becoming the first medical-grade EEG amplifier manufacturer in Taiwan.
Contact Information
Name：Amy Tseng
Tel：0911-128-750
Address：2F., No.578, Ruiguang Rd.Neihu Dist., Taipei City 114, Taiwan (R.O.C.)
Patents：
I782282
